Cargando…
Renal Amyloidosis and Crohn Disease
Background: Secondary amyloidosis, a rare complication of Crohn disease (CD), is triggered by persistent systemic inflammation. Kidney involvement is the most frequent manifestation and is often characterized by nephrotic syndrome and kidney failure. This complication usually appears in patients wit...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academic Division of Ochsner Clinic Foundation
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442223/ https://www.ncbi.nlm.nih.gov/pubmed/34566512 http://dx.doi.org/10.31486/toj.20.0129 |
_version_ | 1783752968730836992 |
---|---|
author | Barahona-Correa, Julián E. Morales, Samuel-David Andrade-Pérez, Rafael Hani, Albis |
author_facet | Barahona-Correa, Julián E. Morales, Samuel-David Andrade-Pérez, Rafael Hani, Albis |
author_sort | Barahona-Correa, Julián E. |
collection | PubMed |
description | Background: Secondary amyloidosis, a rare complication of Crohn disease (CD), is triggered by persistent systemic inflammation. Kidney involvement is the most frequent manifestation and is often characterized by nephrotic syndrome and kidney failure. This complication usually appears in patients with long-standing disease and is associated with increased morbidity and mortality risk. Diagnosis is by microscopic amyloid observation of tissue biopsy, and when the diagnosis is confirmed, the therapeutic objective is disease activity control. Response assessment is challenging because of a lack of reliable biomarkers. Case Report: A 56-year-old male with a long-standing history of CD treated with a tumor necrosis factor-α inhibitor presented with an acute elevation of creatinine in association with clinical and laboratory markers of nephrotic syndrome. Kidney biopsy revealed renal amyloidosis. After treatment adjustment, although a stable creatinine was achieved, the patient had persistent impaired glomerular filtration rate. Conclusion: As a systemic chronic inflammatory disorder, CD may present multisystemic morbidity, for which increased awareness among gastroenterologists is warranted. Renal amyloidosis is an infrequent extraintestinal complication of CD that may lead to chronic kidney impairment. Although evidence-based treatment is lacking, disease activity control is pivotal for management. |
format | Online Article Text |
id | pubmed-8442223 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Academic Division of Ochsner Clinic Foundation |
record_format | MEDLINE/PubMed |
spelling | pubmed-84422232021-09-23 Renal Amyloidosis and Crohn Disease Barahona-Correa, Julián E. Morales, Samuel-David Andrade-Pérez, Rafael Hani, Albis Ochsner J Case Reports and Clinical Observations Background: Secondary amyloidosis, a rare complication of Crohn disease (CD), is triggered by persistent systemic inflammation. Kidney involvement is the most frequent manifestation and is often characterized by nephrotic syndrome and kidney failure. This complication usually appears in patients with long-standing disease and is associated with increased morbidity and mortality risk. Diagnosis is by microscopic amyloid observation of tissue biopsy, and when the diagnosis is confirmed, the therapeutic objective is disease activity control. Response assessment is challenging because of a lack of reliable biomarkers. Case Report: A 56-year-old male with a long-standing history of CD treated with a tumor necrosis factor-α inhibitor presented with an acute elevation of creatinine in association with clinical and laboratory markers of nephrotic syndrome. Kidney biopsy revealed renal amyloidosis. After treatment adjustment, although a stable creatinine was achieved, the patient had persistent impaired glomerular filtration rate. Conclusion: As a systemic chronic inflammatory disorder, CD may present multisystemic morbidity, for which increased awareness among gastroenterologists is warranted. Renal amyloidosis is an infrequent extraintestinal complication of CD that may lead to chronic kidney impairment. Although evidence-based treatment is lacking, disease activity control is pivotal for management. Academic Division of Ochsner Clinic Foundation 2021 2021 /pmc/articles/PMC8442223/ /pubmed/34566512 http://dx.doi.org/10.31486/toj.20.0129 Text en ©2021 by the author(s); Creative Commons Attribution License (CC BY) https://creativecommons.org/licenses/by/4.0/©2021 by the author(s); licensee Ochsner Journal, Ochsner Clinic Foundation, New Orleans, LA. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (creativecommons.org/licenses/by/4.0/legalcode) that permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Case Reports and Clinical Observations Barahona-Correa, Julián E. Morales, Samuel-David Andrade-Pérez, Rafael Hani, Albis Renal Amyloidosis and Crohn Disease |
title | Renal Amyloidosis and Crohn Disease |
title_full | Renal Amyloidosis and Crohn Disease |
title_fullStr | Renal Amyloidosis and Crohn Disease |
title_full_unstemmed | Renal Amyloidosis and Crohn Disease |
title_short | Renal Amyloidosis and Crohn Disease |
title_sort | renal amyloidosis and crohn disease |
topic | Case Reports and Clinical Observations |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442223/ https://www.ncbi.nlm.nih.gov/pubmed/34566512 http://dx.doi.org/10.31486/toj.20.0129 |
work_keys_str_mv | AT barahonacorreajuliane renalamyloidosisandcrohndisease AT moralessamueldavid renalamyloidosisandcrohndisease AT andradeperezrafael renalamyloidosisandcrohndisease AT hanialbis renalamyloidosisandcrohndisease |